USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses

Nature Immunology

Volumn 15, Issue 6, 2014, Pages 562-570

  Zou, Qiang ^a   Jin, Jin ^a   Hu, Hongbo ^a   Li, Haiyan S ^a   Romano, Simona ^a,b   Xiao, Yichuan ^a   Nakaya, Mako ^a   Zhou, Xiaofei ^a   Cheng, Xuhong ^a   Yang, Peirong ^a   Lozano, Guillermina ^a,c   Zhu, Chengming ^a,c   Watowich, Stephanie S ^a,c   Ullrich, Stephen E ^a,c   Sun, Shao Cong ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DEUBIQUITINASE; GAMMA INTERFERON; INTERLEUKIN 2; NFATC2 PROTEIN; PROTEIN MDM2; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; USP15 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BACTERIAL INFECTION; BONE MARROW CELL; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVE SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOBLOTTING; IMMUNOCOMPETENT CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LISTERIOSIS; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; T CELL RESPONSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ADOPTIVE TRANSFER; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; HCT116 CELLS; HUMANS; LEUPEPTINS; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NFATC TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS C-MDM2; TH1 CELLS; TUMOR ESCAPE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-SPECIFIC PROTEASES; UBIQUITINATION;

EID: 84901246134     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2885     Document Type: Article

References (46)

1. Liu, Y.C., Penninger, J. & Karin, M. Immunity by ubiquitylation: A reversible process of modification. Nat. Rev. Immunol. 5, 941-952 (2005
2. Lipkowitz, S. & Weissman, A.M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 11, 629-643 (2011
3. Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425-479 (1998
4. Chen, Z.J. & Sun, L.J. Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33, 275-286 (2009
5. Kulathu, Y. & Komander, D. Atypical ubiquitylation-The unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat. Rev. Mol. Cell Biol. 13, 508-523 (2012
6. Li, W. et al. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS ONE 3, e1487 (2008
7. Li, Q. & Lozano, G. Molecular pathways: Targeting Mdm2 and Mdm4 in cancer therapy. Clin. Cancer Res. 19, 34-41 (2013
8. Wade, M., Li, Y.C. & Wahl, G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83-96 (2013
9. Shangary, S. & Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49, 223-241 (2009
10. Reyes-Turcu, F.E., Ventii, K.H. & Wilkinson, K.D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78, 363-397 (2009
11. Komander, D., Clague, M.J. & Urbe, S. Breaking the chains: Structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 10, 550-563 (2009
12. Sun, S.C. Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 8, 501-511 (2008
13. Fraile, J.M., Quesada, V., Rodriguez, D., Freije, J.M. & Lopez-Otin, C. Deubiquitinases in cancer: New functions and therapeutic options. Oncogene 31, 2373-2388 (2012
14. Harhaj, E.W. & Dixit, V.M. Regulation of NF-kappaB by deubiquitinases. Immunol. Rev. 246, 107-124 (2012
15. Baker, R.T., Wang, X.W., Woollatt, E., White, J.A. & Sutherland, G.R. Identification, functional characterization, and chromosomal localization of USP15, a novel human ubiquitin-specific protease related to the UNP oncoprotein, and a systematic nomenclature for human ubiquitin-specific proteases. Genomics 59, 264-274 (1999
16. Vos, R.M., Altreuter, J., White, E.A. & Howley, P.M. The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability. J. Virol. 83, 8885-8892 (2009
17. Inui, M. et al. USP15 is a deubiquitylating enzyme for receptor-Activated SMADs. Nat. Cell Biol. 13, 1368-1375 (2011
18. Eichhorn, P.J. et al. USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma. Nat. Med. 18, 429-435 (2012
19. Hetfeld, B.K. et al. The zinc finger of the CSN-Associated deubiquitinating enzyme USP15 is essential to rescue the E3 ligase Rbx1. Curr. Biol. 15, 1217-1221 (2005
20. Wakil, A.E., Wang, Z.E., Ryan, J.C., Fowell, D.J. & Locksley, R.M. Interferon gamma derived from CD4(+) T cells is sufficient to mediate T helper cell type 1 development. J. Exp. Med. 188, 1651-1656 (1998
21. Smith-Garvin, J.E., Koretzky, G.A. & Jordan, M.S. T cell activation. Annu. Rev. Immunol. 27, 591-619 (2009
22. Kiani, A. et al. Regulation of interferon-gamma gene expression by nuclear factor of activated T cells. Blood 98, 1480-1488 (2001
23. Macian, F. NFAT proteins: Key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472-484 (2005
24. Yoeli-Lerner, M. et al. Akt blocks breast cancer cell motility and invasion through the transcription factor. NFAT. Mol. Cell 20, 539-550 (2005
25. Harper, S., Besong, T.M., Emsley, J., Scott, D.J. & Dreveny, I. Structure of the USP15 N-Terminal domains: A beta-hairpin mediates close association between the DUSP and UBL domains. Biochemistry 50, 7995-8004 (2011
26. Kitagaki, J., Agama, K.K., Pommier, Y., Yang, Y. & Weissman, A.M. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol. Cancer Ther. 7, 2445-2454 (2008
27. Manfredi, J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 24, 1580-1589 (2010
28. Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004
29. Ovaa, H. et al. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc. Natl. Acad. Sci. USA 101, 2253-2258 (2004
30. Take, Y., Kumano, M., Teraoka, H., Nishimura, S. & Okuyama, A. DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-Type p53 induced by adriamycin. Biochem. Biophys. Res. Commun. 221, 207-212 (1996
31. Cheok, C.F., Kua, N., Kaldis, P. & Lane, D.P. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-Type p53. Cell Death Differ. 17, 1486-1500 (2010
32. Overwijk, W.W. & Restifo, N.P. B16 as a mouse model for human melanoma. Curr. Protoc. Immunol. 20, 21 (2001
33. Kennedy, R. & Celis, E. Multiple roles for CD4+ T cells in anti-Tumor immune responses. Immunol. Rev. 222, 129-144 (2008
34. Li, M. et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653 (2002
35. Kon, N. et al. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 29, 1270-1279 (2010
36. Loch, C.M. & Strickler, J.E. A microarray of ubiquitylated proteins for profiling deubiquitylase activity reveals the critical roles of both chain and substrate. Biochim. Biophys. Acta 1823, 2069-2078 (2012
37. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012
38. Montes de Oca Luna, R., Wagner, D.S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206 (1995
39. Chang, M. et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat. Immunol. 12, 1002-1009 (2011
40. Reiley, W.W. et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 204, 1475-1485 (2007
41. Sun, S-C., Ganchi, P.A., Beraud, C., Ballard, D.W. & Greene, W.C. Autoregulation of the NF-κB transactivator Rel A (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Proc. Natl. Acad. Sci. USA 91, 1346-1350 (1994
42. Hassink, G.C. et al. The ER-resident ubiquitin-specific protease 19 participates in the UPR and rescues ERAD substrates. EMBO Rep. 10, 755-761 (2009
43. Lu, Y. et al. Th9 cells promote antitumor immune responses in vivo. J. Clin. Invest. 122, 4160-4171 (2012
44. Cvijic, M.E., Xiao, G. & Sun, S.C. Study of T-cell signaling by somatic cell mutagenesis and complementation cloning. J. Immunol. Methods 278, 293-304 (2003
45. Foulds, K.E. et al. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. 168, 1528-1532 (2002
46. Edwards, L.A. et al. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene 24, 3596-3605 (2005